Syndax Pharmaceuticals Archives

Tag: Syndax Pharmaceuticals

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

December 7, 2024

[ad_1] – 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of […]

Continue Reading →

Tag: Syndax Pharmaceuticals

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

#Rosal Top Picks

Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

Max Stock Limited Announces Immediate report on Termination of Shareholders’ Agreement and Management Services Agreement

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Mill Creek Announces Groundbreaking of Amavi Northwest Austin

7-Eleven, Inc. Makes Mornings Flavorful with New Breakfast Favorites and Limited-Time Deals

Natural Grocers® Launches Free Three-Part Class Series to Help Customers Hack Their Health

Mantle Vault Hits $100M Milestone, Cementing Bybit as Premier Gateway for On-Chain Yield

Recent Posts

Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

Max Stock Limited Announces Immediate report on Termination of Shareholders’ Agreement and Management Services Agreement

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Mill Creek Announces Groundbreaking of Amavi Northwest Austin

7-Eleven, Inc. Makes Mornings Flavorful with New Breakfast Favorites and Limited-Time Deals

eDisasterX